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The t(8;21) and inv(16) chromosomal aberrations
generate the oncoproteins AML1-ETO (A-E) and
CBFb-SMMHC (C-S). The role of these oncoproteins
in acute myeloid leukemia (AML) etiology has been
well studied. Conversely, the function of native
RUNX1 in promoting A-E- and C-S-mediated leuke-
mias has remained elusive. We show that wild-type
RUNX1 is required for the survival of t(8;21)-
Kasumi-1 and inv(16)-ME-1 leukemic cells. RUNX1
knockdown in Kasumi-1 cells (Kasumi-1RX1-KD)
attenuates the cell-cycle mitotic checkpoint, leading
to apoptosis, whereas knockdown of A-E in Kasumi-
1RX1-KD rescues these cells. Mechanistically, a deli-
cate RUNX1/A-E balance involving competition for
common genomic sites that regulate RUNX1/A-E
targets sustains the malignant cell phenotype. The
broad medical significance of this leukemic cell
addiction to native RUNX1 is underscored by clinical
data showing that an active RUNX1 allele is usually
preserved in both t(8;21) or inv(16) AML patients,
whereas RUNX1 is frequently inactivated in other
forms of leukemia. Thus, RUNX1 and its mitotic con-
trol targets are potential candidates for new thera-
peutic approaches.INTRODUCTION
Acute myeloid leukemia (AML) is characterized by a block in
early progenitor differentiation leading to accumulation of imma-
ture, highly proliferative leukemic stem cells (LSCs) in bone
marrow (BM) and blood (Rosenbauer et al., 2005). Chromo-
some-21-encoded transcription factor (TF) RUNX1 (a.k.a.
AML1) is a frequent target of various chromosomal transloca-
tions (Lam and Zhang, 2012). The most prevalent translocation
in AML is t(8;21) (Hatlen et al., 2012; Mu¨ller et al., 2008), which
creates a fused gene product designated AML1-ETO (A-E). ItCell Recontains the DNA-binding domain of RUNX1 (the runt domain
[RD]) linked to the major part of the chromosome-8-encoded
protein ETO (Erickson et al., 1992; Miyoshi et al., 1993), which
by itself lacks DNA-binding capacity (Davis et al., 2003).
RUNX1 is a key hematopoietic gene expression regulator in
embryos and adults (Cameron and Neil, 2004; de Bruijn and
Speck, 2004; Wang et al., 1996). Its major cofactor, core-binding
factor b (CBFb), is essential for RUNX1 function (Miller et al.,
2001, 2002). On the other hand, ETO is a transcriptional
repressor (Davis et al., 2003) that is known to interact with core-
pressors such as NCoR/SMRT, mSin3a, and histone deacety-
lases (HDACs) (reviewed in Hug and Lazar, 2004). Of note,
although the ETO gene is normally expressed in the gut and
CNS (Lam and Zhang, 2012), the t(8;21) translocation places it
under transcriptional control of RUNX1 regulatory elements
(Bee et al., 2009; Ghozi et al., 1996; Levanon et al., 2001). This
occurrence evokes expression of A-E in the myeloid cell lineage.
The prevailing notion is that A-E binds to RUNX1 target genes
and acts as dominant-negative regulator, thereby producing
conditions that resemble the RUNX1/ phenotype (reviewed
inGoyama andMulloy, 2011; Hatlen et al., 2012; Lamand Zhang,
2012; Licht, 2001). Consistent with this concept, mice express-
ing an A-E knockin allele (Okuda et al., 1998; Yergeau et al.,
1997) display early embryonic lethality and hematopoietic de-
fects similar to those observed in Runx1/ mice (reviewed in
Goyama and Mulloy, 2011; Hatlen et al., 2012; Lam and Zhang,
2012; Licht, 2001). However, it has also been shown that A-E-
mediated leukemogenicity involves other events that affect
gene regulation, in addition to repression of RUNX1 targets
(Bakshi et al., 2008; Hatlen et al., 2012; Hyde and Liu, 2010;
Lam and Zhang, 2012; Okumura et al., 2008). Reduction of A-E
expression in leukemic cells by siRNA restores myeloid differen-
tiation (Dunne et al., 2006; Heidenreich et al., 2003; Martinez
et al., 2004) and delays in vivo tumor formation (Martinez Soria
et al., 2009). Depletion of A-E in t(8;21)+ AML cells causes
genome-wide changes in chromatin structure leading to redistri-
bution of RUNX1 occupancy and inhibition of cell self-renewal
capacity (Ptasinska et al., 2012).
An additional AML subtype associated with altered RUNX1
activity involves the chromosomal aberrations inv(16)(p13q22)
and t(16;16)(p13q22) (abbreviated as inv(16)). This inversionports 4, 1131–1143, September 26, 2013 ª2013 The Authors 1131
fuses the chromosome 16q22-encoded CBFb gene with the
MYH11 gene, which resides at 16p13 and encodes smooth-
muscle myosin heavy chain (SMMHC). The resulting chimeric
oncoprotein is known as CBFb-SMMHC (Arthur and Bloomfield,
1983; Le Beau et al., 1983). Similarly to A-E, CBFb-SMMHC
(C-S) is a dominant inhibitor of RUNX1 activity (Castilla et al.,
1996; Lukasik et al., 2002) that impairs myeloid differentiation
and contributes to AML development (Castilla et al., 2004; Kuo
et al., 2006).
Although the central role of A-E in the leukemic process has
been extensively studied, the potential role of the wild-type
(WT) RUNX1 allele in t(8;21) AML etiology remains unclear
(Goyama and Mulloy, 2011). Similarly, the function of RUNX1 in
the development of inv(16) AML is completely unknown. We
used the AML cell lines t(8;21) Kasumi-1 (Asou et al., 1991) and
inv(16) ME-1 (Yanagisawa et al., 1991) to evaluate the possible
involvement of WT RUNX1 in A-E- and C-S-mediated leukemo-
genesis. We show that t(8;21) Kasumi-1 and inv(16) ME-1 AML
cells are physiologically dependent on RUNX1 activity for their
survival. The broad medical significance of this leukemic cell
addiction to native RUNX1 is underscored by clinical data
showing that an active RUNX1 allele is maintained in both
t(8;21) and inv(16) AML patients, whereas RUNX1 is frequently
inactivated in other forms of AML (Schnittger et al., 2011; Tang
et al., 2009; reviewed in Goyama and Mulloy, 2011).
Knockdown (KD) of RUNX1 in Kasumi-1 cells (Kasumi-1RX1-KD)
results in A-E-mediated, caspase-dependent apoptosis. This
apoptosis is triggered by the dysregulated expression of a
gene subset that is crucial for mitotic functions, including mitotic
checkpoint signaling. Significantly, KD of A-E in Kasumi-1RX1-KD
cells evades this apoptosis and rescues Kasumi-1RX1-KD,
whereas KD of A-E diminishes the leukemogenic cell phenotype.
Thus, a delicate balance between A-E and WT RUNX1 activities
is required to maintain the malignant phenotype of Kasumi-1
cells. We elucidated the mechanism underlying this RUNX1/
A-E balance by using combined differential gene expression
and genome-wide chromatin immunoprecipitation sequencing
(ChIP-seq) analyses. This analysis identified a subset of
RUNX1/A-E common responsive genes that are inversely regu-
lated by these two TFs and singled out the most critical
RUNX1 targets. Our findings uncovered a previously unrecog-
nized role of RUNX1 in the regulation of mitotic checkpoint
events, through which it prevents the inherent apoptotic pro-
cess in t(8;21) cells and facilitates leukemogenesis. These data
implicate RUNX1 and its downstream mitotic regulators as
potential targets for new therapeutic treatments of t(8;21) and
inv(16) leukemias.
RESULTS
Expression of WT RUNX1 Is Essential for t(8;21) AML
Kasumi-1 Cell Survival
We assessed the cell-phenotypic consequences of RUNX1 KD
in Kasumi-1 cells to directly address the possibility that native
RUNX1 function is required for the leukemogenic process in
t(8;21) AML cells. Specific siRNA-oligo nucleotides that target
RUNX1 regions absent from the A-E transcript were used to
attenuate the expression of RUNX1 (Figures 1A and S1A). Cell-1132 Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The Aucycle analysis of Kasumi-1RX1-KD cells revealed a prominent in-
crease in the proportion of cells bearing subG1 DNA content
and a significant decrease in the proportions of S and G2/M
phases as compared with cells transfected with control nontar-
geting (NT) siRNA (Kasumi-1Cont; Figures 1B, 1C, S1B, and
S1C). This abnormal Kasumi-1RX1-KD cell cycle was associated
with an elevated percentage of both Annexin-V+ viable and
nonviable cells (Figure 1D) and a 7-fold decrease in the total
number of viable cells (Figure 1E). These results indicated that
KD of RUNX1 induces apoptotic cell death in Kasumi-1RX1-KD.
Transfection of an alternative siRNA oligo directed against a
differentRUNX1 region (indicated by the orange bar in Figure 1A)
confirmed that apoptosis resulted from decreased RUNX1 activ-
ity (Figure S2) and ruled out the possibility of a siRNA-specific
off-target effect.
We next sought to determine whether Kasumi-1RX1-KD cell
death involves the mitochondrial permeability transition (MPT).
Flow-cytometry imaging (ImageStream System) analysis
demonstrated that increased Kasumi-1RX1-KD cell apoptosis
was associated with loss of mitochondrial membrane potential
(Figures 1F and 1G), suggesting the involvement of MPT in
inducing cell death. To assess whether this RUNX1 KD-triggered
apoptosis involved caspase activation, we analyzed Kasumi-
1RX1-KD and Kasumi-1Cont cell cycles in the presence of the
broad-spectrum caspase inhibitor Z-VAD-FMK. Significantly,
Z-VAD-FMK completely blocked apoptosis in Kasumi-1RX1-KD
cells, as reflected in a profound decrease of the subG1 fraction
to a level similar to that of Kasumi-1Cont cells (Figure 1H). Of
note, the majority of Z-VAD-FMK-rescued Kasumi-1RX1-KD cells
accumulated at cell-cycle G1 andG2/M phases (Figure 1H), sug-
gesting that RUNX1KD-evoked apoptosis involved impairedG2/
M-to-G1 and G1-to-S transitions. Using Z-VAD-FMK-treated
cells, we also recorded reduced RUNX1 protein levels in
Kasumi-1RX1-KD cells (Figure 1I). Taken together, the results of
the cell-cycle analysis, Annexin-V staining, viability assay,
ImageStream analysis, and Z-VAD-FMK experiments demon-
strate that attenuation of WT RUNX1 expression in Kasumi-1
cells triggers pronounced caspase-dependent apoptosis asso-
ciated with changes in mitochondrial permeability. The most
likely implication of these data is that WT RUNX1 plays an antia-
poptotic role in t(8;21) AML cells and its activity is compromised
by the oncogenic A-E bearing the RUNX RD. Therefore, the
remaining WT RUNX1 activity is indispensable for cell viability.
A-E KD Rescues Kasumi-1RX1-KD Cells from Apoptosis
To further investigate the involvement of WTRUNX1 in the devel-
opment of A-E-mediated t(8;21) AML, we used siRNA specific for
the translocated transcripts to KD A-E (Kasumi-1AE-KD) expres-
sion (Figures 2A and S3A, top). Kasumi-1AE-KD cells displayed
decreased proliferation (Figure S3A, bottom) and increased
myeloid differentiation (Figures S3B and S3C), as was previously
noted (Dunne et al., 2006; Heidenreich et al., 2003; Martinez
et al., 2004; Ptasinska et al., 2012), as well as amarked reduction
in the proportion of CD34+CD38 leukemogenic cell population
(Figures S3B and S3C). We next examined the impact of A-E
KD on the cell phenotype of Kasumi-1RX1-KD. Interestingly, the
double-KD cells (Kasumi-1RX1/AE-KD) displayed an apoptotic
level similar to or even lower than that of control cells (Figuresthors
Figure 1. WT RUNX1 Prevents Apoptosis of the t(8;21) Kasumi-1 Leukemic Cell Line
(A) Upper panel: scheme of RUNX1 (blue) and RUNX1-ETO (A-E, blue-red) transcripts indicating regions targeted by the siRNAs used to knock down expression
of either RUNX1 (bars underneath RUNX1 marked in green and orange) or A-E (black bar underneath the A-E fusion region). Lower panel: qRT-PCR analysis of
siRNA-mediated RUNX1 KD. Total RNA was isolated 24 hr after electroporation of RUNX1-targeting or NT control siRNA. The data shown represent mean
expression ± SE. Shown are results from one of three experiments with the same findings. Primers used for qRT-PCR are presented in Table S7.
(B and C) Cell-cycle analysis 8 days posttransfection with either RUNX-targeting or NT siRNA.
(B) Cells were subjected to two successive transfections (at days 0 and 4) with either RUNX1-targeting or NT siRNA. Propidium iodide (PI) was used to assess
cellular DNA content by FACS analysis. Bar numbers indicate the relative size (in %) of the labeled population out of total cells. Indicated cell-cycle phases:
subG1, G1, S, and G2M (see also Figure S1).
(C) Histograms summarizing the distribution of cell population as analyzed in (B). Data represent the mean ± SD values of five independent experiments.
(D) Increased Kasumi-1RX1-KD cell apoptosis. Cells were stained with Annexin-V following siRNA-mediated RUNX1 KD. Staining with the eFluor780 viability dye
marked dead/late apoptotic cells. Results from one of two experiments with the same findings are shown. See also Figure S2.
(E) Diminished Kasumi-1RX1-KD cell viability. Eight days posttransfection with either RUNX1-targeting or NT siRNA, the total number of viable cells was assessed
via standard hemocytometer cell counting excluding trypan-blue-stained cells. Data represent the mean ± SD values of three independent experiments.
(F and G) RUNX1 KD-induced apoptosis is associated with loss of mitochondrial membrane potential.
(F) ImageStream System analysis of Kasumi-1 cells incubated for 4 days with RUNX1-targeting or NT siRNA and stained for cell mitochondria and DNA content.
Bright-field visualization indicates cell apoptotic morphology. Green fluorescent dye (Mitogreen) stains mitochondria in both live and dead cells. Red dye
(MitoTracker Red CMXRos) stains mitochondria only in live cells, depends on mitochondrial membrane potential, and indicates MPT. DNA was stained with
DRAQ5. Cells with a low red/green ratio and low DNA signal were defined as apoptotic. Results from one of two experiments with the same findings are shown.
(G) Histograms presenting quantitative data of ImageStream System analysis for Kasumi-1RX1-KD and Kasumi-1Cont as mean ± SD of two biological repeats.
(H) Caspase inhibition rescues Kasumi-1RX1-KD from apoptosis. Three days after siRNA delivery, cells were incubated with either Z-VAD-FMK (50 mM) or vehicle
(DMSO) for an additional 24 hr. Histograms show the distribution of cells among cell-cycle phases determined as detailed above. The data shown represent the
mean ± SD of four independent experiments.
(I) Western blot analysis demonstrating RUNX1 KD. Cells transfected with RUNX1-targeting or NT siRNA were incubated for 72 hr followed by additional 24 hr
incubation with Z-VAD-FMK (50 mM). Blots were reacted with Ab against RUNX1-N terminus or Lamin. Results from one of two experiments with the same
findings are shown. See also Figure S1A.
Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The Authors 1133
Figure 2. Rescue of Kasumi-1RX1-KD Cells from Apoptosis by KD
of A-E
(A) Specific reduction of A-E expression in Kasumi-1AE-KD cells. Expression of
A-E and RUNX1 following cell transfection with A-E- or RUNX1- targeting
1134 Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The Au2B and 2C). This observation is consistent with the possibility
that A-E activity contributed to Kasumi-1RX1-KD cell apoptosis,
underscoring the importance of the balance between A-E and
RUNX1 activities for maintaining leukemogenicity. It further sug-
gests that A-E and RUNX1 serve as positive and negative
apoptosis regulators, respectively, by controlling the expression
of their shared target genes in an opposing manner.
RUNX1- and A-E-Responsive Genes Are Inversely
Regulated
We next sought to identify RUNX1- and A-E-responsive genes
that participate in the interplay between the two TFs, thereby
affecting Kasumi-1 cell survival. First, we assessed the global
gene expression alterations in response to KD of either RUNX1
or A-E by analyzing the Kasumi-1RX1-KD or Kasumi-1AE-KD cell
transcriptomes compared with that of Kasumi-1Cont (Tables S1
and S2). Importantly, the overall gene expression profile in
response to KD of A-E or RUNX1 was inversely correlated (Fig-
ure 3A, R2 = 0.33). Genes that were repressed following
RUNX1 KD tended to be upregulated following A-E KD and
vice versa (Figure 3A).
Of the 754 genes that responded to KD of either A-E or
RUNX1, 109were common and affected by KD of either one (Fig-
ure 3B). The majority of these A-E/RUNX1 common genes (95 of
109) responded inversely to the KD of RUNX1 or A-E (Table S3).
Interestingly, analysis of these inversely A-E/RUNX1-regulated
genes (using Ingenuity System IPA) revealed a significant asso-
ciation with terms of cell death and/or apoptosis (Table S4).
Thus, the gene expression data supported the idea that disrup-
tion of the cellular balance between RUNX1 and A-E activities is
the underlying cause of Kasumi-1RX1-KD cell apoptosis. We
therefore further characterized this regulatory interplay by
analyzing the genomic occupancy of the two TFs.
RUNX1 and A-E Genomic Occupancy Patterns
To selectively map the genomic occupancy of either RUNX1 or
A-E, we conducted ChIP-seq using anti-RUNX1-C terminus or
anti-ETO specific antibodies (Figure 3C). Data analysis revealed
14,247 RUNX1-bound genomic regions and a comparable num-
ber of A-E bound regions (13,070). As could have been predicted
from their common DNA-binding RD, the genomic occupancy of
RUNX1 and A-E was highly correlated (Figures 3D and 3E).
Despite this strong quantitative correlation, we also noted a(indicated in Figure 1A by black and green bars, respectively) or control siRNAs
was analyzed by qRT-PCR (left panel) 24 hr posttransfection, and by western
blotting (right panel) using anti ETO, anti RUNX1, or anti lamin Abs 96 hr
posttransfection. To rigorously monitor the specificity of A-E KD, the blot was
divided as indicated by the black arrow, and the upper and lower parts were
reacted with anti-ETO or anti-RUNX1 C-terminal Abs, respectively (Extended
Experimental Procedures).
(B and C) KD of A-E rescues Kasumi-1 cells from RUNX1 KD-induced
apoptosis. Cells were cotransfected with a 1:1 mixture of RUNX1 and A-E
targeting siRNAs or separately with RUNX1 siRNA, A-E siRNA, or NT siRNA.
(B) Following incubation for 8 days, cells were stained with PI and analyzed by
FACS for cell cycle.
(C) Histograms show the distribution of cells among cell-cycle phases. Data
shown represent the mean ± SD of four independent biological repeats.
See also Figure S3.
thors
Figure 3. Gene Expression and ChIP-Seq
Analysis of A-E- and RUNX1-Occupied
Genomic Regions
(A) Gene expression profiling of Kasumi-1
following KD of either RUNX1 or A-E revealed a
significant inverse gene expression response as
evidenced by a negative Spearman correlation
(R2 = 0.33).
(B) Venn diagram showing the number and relative
proportion of genes whose expression signifi-
cantly changed following KD of either RUNX1 or
A-E. The differential expression cutoff was set
to a minimal absolute fold change of 1.4 and
maximal p value of 0.05. See also Tables S1, S2,
S3, and S4.
(C) Selective detection of RUNX1 or A-E proteins in
Kasumi-1 cells. Western blotting of Kasumi-1
nuclear extracts using antibodies raised against
the RUNX1-C terminus (left lane) or against
ETO (right lane). The central lane was reacted with
anti-RUNX1-N terminus antibody detecting both
RUNX1 and A-E.
(D) Venn diagram of the number and relative pro-
portion of RUNX1- and/or A-E-occupied genomic
regions recorded by ChIP-seq experiments using
anti-RUNX1-C terminus or anti-ETO.
(E) Comparison of RUNX1 and/or A-E binding
affinity detected by ChIP-seq analysis. Binding of
A-E and RUNX1 strongly correlated (Pearson R2 =
0.72, p value < 2 3 1016).
(F and G) Enrichment of genes up- and down-
regulated in response to KD of RUNX1 (F) and A-E
(G), respectively. Data were compiled using inte-
grated results of ChIP-seq and gene expression.
Shown are enrichment ratios for up- and down-
regulated genes computed as the fraction of
bound regulated genes divided by the global
fraction of bound genes. Bars mark binomial SDs
for the enrichment estimates.
See also Figure S3.spectrum of differential A-E/RUNX1 binding (Figures 3E and
S3D–S3G), suggesting variable binding affinities of the two TFs
at loci with different genomic contexts.
To study the impact of binding patterns on the transcriptional
response to KD of either RUNX1 or A-E, we integrated the
ChIP-seq and gene expression data sets. A significant number
of genes proximal to RUNX1/A-E-shared regions were downre-
gulated following RUNX1 KD and upregulated in response to
A-E KD (Figures 3F and 3G), supporting the notion that
direct competition between the two TFs is the underlying mech-
anism driving the leukemogenic transcriptional program. Specif-
ically, due to their common DNA-binding domain, RUNX1 and
A-E occupy a shared subset of target genes. Because these
genes are oppositely regulated by the two TFs, the cellular
phenotypes of RUNX1 and A-E KD differ. However, the
opposing regulatory effect of A-E and RUNX1 was also mani-Cell Reports 4, 1131–1143, Sepfested in inverse regulation of their
uniquely occupied genes (Figures 3F
and 3G). This observation suggests that
the two TFs might also compete indi-rectly due to distinct sequence affinities and/or interaction
with cooperating TFs.
Comparative Sequence Analysis of Uniquely Occupied
RUNX1/A-E Genomic Regions
The opposing transcriptional responses of RUNX1 and A-E
shared and unique target genes prompted us to further charac-
terize the properties of A-E- and/or RUNX1-bound regions. In
comparison with uniquely A-E-bound regions, a significantly
higher proportion of RUNX1-unique peaks were localized at
the vicinity of the transcription start site (TSS; Figure 4A), sug-
gesting that RUNX1 has an advantage over A-E in binding to
promoter regions in Kasumi-1 cells. Sequence analysis of
genomic regions uniquely bound by either A-E or RUNX1 re-
vealed a significantly lower frequency of the canonical RUNX
motif within A-E-bound regions (Figure 4B, left). On the othertember 26, 2013 ª2013 The Authors 1135
Figure 4. Comparative Sequence Analysis of
RUNX1- and A-E-Bound Regions
(A) Frequency of uniquely bound RUNX1 or A-E
proximal to annotated TSS. Bound TF was defined
as proximal when the distance to annotated TSS
was <500 bp.
(B) Enrichment of the canonical RUNX motif (left)
and a RUNX-variant motif (right) in regions uniquely
bound by RUNX1 or A-E. The level of motif
enrichment is coded numerically (0 = no enrich-
ment, 10 = high enrichment) and by color intensity
in the Venn diagrams.
(C) The ratio of ChIP-seq binding intensities of
RUNX1 and A-E is positively correlated with the
relative enrichment of the canonical and variant
RUNX motifs. Shown are binding intensities color-
coded according to motif enrichments ratios:
blue, high enrichment of canonical RUNX motif
(observed mostly at upper left); red, high enrich-
ment of variant RUNX motif (observed mostly at
lower right).
(D) Enrichment of the ETS (upper) and AP4 (lower)
TF motifs among unique and common RUNX1/A-E
bound regions.Motifs were identified de novo using
A-E and RUNX1 ChIP-seq genomic bound regions.
The level of enrichment is indicated both numeri-
cally and by color as in (B). See also Figure S4.hand, these A-E-occupied regions exhibited a higher frequency
of a variant RUNX motif compared with the uniquely bound
RUNX1 peaks (Figure 4B, right). Interestingly, the ratio between
the two motifs quantitatively predicted the ratio between RUNX1
and A-E ChIP-seq enrichment (Figure 4C, p < 2.2 3 1016). The
enrichment of promoter occupancy by RUNX1 and the differen-
tial affinities of A-E and RUNX1 to the variant and canonical
RUNX motifs suggest that subtle sequence preferences contrib-
uted to the differential binding and consequent biological activity
of the two TFs.
Further sequence analysis of RUNX1- and A-E-occupied re-
gions revealed that while both bound regions were enriched for
the ETS TF motif (Figure 4D, top), only A-E unique regions
were specifically enriched for the palindromic motif CAGCTG,
bound by the E box TF AP4 (Figure 4D, bottom). The latter obser-
vation is consistent with previous studies (Gardini et al., 2008;
Zhang et al., 2004) indicating that A-E interactions with E box
proteins facilitate its binding to the DNA, and with the more
recent finding of enrichment in E-Box-binding proteins among
A-E-unique peaks (Ptasinska et al., 2012). Given that AP4 is
highly expressed in Kasumi-1 cells (Figure S4A), we performed
AP4 ChIP-seq and compared the distribution of AP4-binding
sites with the A-E and RUNX1 occupancy profiles. Although sig-
nificant numbers of ChIP-seq peaks were common to the three
TFs, there was no preference for A-E/AP4 co-occupancy
compared with that of RUNX1/AP4 (Figure S4B). This finding
would argue that AP4 is unlikely to be the only E box TF that1136 Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The Authorspreferentially interacts with A-E. Neverthe-
less, we cannot rule out the possibility that
A-E and AP4 regulate a common subset
of genes in Kasumi-1 cells, potentiallythrough protein-protein interaction as recently reported for AP4
and RUNX1 (Egawa and Littman, 2011). The ChIP-seq analysis
may explain the mechanism underlying the opposing regulatory
effects of RUNX1 and A-E, suggesting that sequence context
and protein-protein interactions play a role in their overall impact
on the cell-transcriptional program.
Gene Expression Analysis of Apoptosis-Inhibited
Kasumi-1RX1-KD Cells Revealed Altered Expression of
Critical Mitotic Progression Genes
Because RUNX1 KD in Kasumi-1 cells triggered extensive
caspase-dependent apoptosis (Figure 1), we sought to identify
the molecular pathways involved in this process. We measured
differential gene expression in Z-VAD-FMK-treated Kasumi-
1RX1-KD cells (Kasumi-1RX1-KD+Z) compared with Z-VAD-FMK-
treated control cells (Kasumi-1Cont+Z; see Figures 1H and 1I).
Gene expression analysis revealed that 920 genes were
differentially expressed in Kasumi-1RX1-KD+Z compared with
Kasumi-1Cont+Z cells (Figure 5A; Table S5). Out of these
RUNX1-responsive genes, 485 and 435 genes were up- or
down-regulated, respectively. Functional annotation analysis
indicated that Kasumi-1RUNX1-KD+Z differentially expressed
genes were highly enriched for genes with critical functions in
mitosis (Table S6). This unique RUNX1-responsive mitotic sub-
set included genes involved in regulation of the mitotic check-
point, also known as the spindle-assembly checkpoint (SAC)
(Lara-Gonzalez et al., 2012). Expression of several key mitotic
Figure 5. Transcriptome Analysis of Z-VAD-FMK-Treated Kasumi-1RX1-KD Cells Highlights a Gene Subset that Is Crucial for Mitotic Function
(A) Gene expression profile of Z-VAD-FMK-treated Kasumi-1RX1-KD cells. A scatterplot of differentially expressed genes in Kasumi-1 cells treated with control NT
or RUNX1-targeting siRNA for 96 hr is shown. Z-VAD-FMK (50 mM) was added for the last 36 hr prior to FACS sorting of FITC+ cells for RNA isolation. Genes that
were up- or down-regulated due to RUNX1 KD are marked by red or blue dots, respectively. The differential expression cutoff was set to a minimal absolute fold
change of 1.4 and maximal p value of 0.05. See also Tables S5 and S6.
(B) qRT-PCR analysis of mitotic genes scored by microarray gene expression. Results are presented as mean ± SE of two biological repeats.
(C–F) RUNX1 and A-E exhibit a similar binding pattern in TOP2A, NEK6, SGOL1, and BUB1 genomic loci. Shown are ChIP-seq tracing wiggle files uploaded to
the UCSC Genome Browser hg18 genome assembly.and SAC genes that were downregulated in Kasumi-1RX1-KD+Z
was validated by quantitative RT-PCR (qRT-PCR; Figure 5B).
Interestingly, among these responsive genes, the genomic loci
of TOP2A, NEK6, SGOL1, and BUB1 exhibited similar ChIP-
seq occupancy of RUNX1 and A-E (Figures 5C–5F). Additionally,
Kasumi-1RX1-KD+Z expression data were also enriched for
decreased expression of genes that are critical for DNA replica-Cell Retion, including PRIM1, ORC1L, RFC1, CDC6, MCM6, and
MCM10 (Table S5). Taken together, these results suggest that
in addition to its requirement in mitosis, RUNX1 might be critical
for the proliferation of Kasumi-1 through its function in G1 and/or
S phases. Collectively, these data are compatible with the pos-
sibility that RUNX1 positively regulates these mitosis-critical
genes, but its KD in Kasumi-1RX1-KD cells enables A-E to bindports 4, 1131–1143, September 26, 2013 ª2013 The Authors 1137
Figure 6. Opposing Effects of A-E and RUNX1 on SAC Signaling in Kasumi-1 Cells
(A and B) SAC signaling is regulated by RUNX1 and A-E. Cells were transfected with the indicated siRNAs and incubated for 72 hr prior to addition of (A) vehicle
(DMSO) or (B) NOC (0.1 mg/ml) for 14 hr thereafter. Cell-cycle analysis was performed by FACS using PI labeling as described in Figure 1B. Bar numbers indicate
the relative population size (in %) out of total cell number. Results from one of three experiments with similar findings are shown.
(C) The relative activity of RUNX1 and A-E impact SAC efficacy and thus a cell’s tendency to undergo apoptosis. Histogram shows the ratio of % cells in G2/M
versus subG1. The ratio calculated for the NT group was considered as one.and repress their expression, resulting in mitotic impairment-
mediated apoptosis.
Opposing Effects of RUNX1 and A-E on SAC Signaling
As a sensitive measurement of SAC activity, we used the micro-
tubule-depolarizing agent nocodazole (NOC), which induces
SAC, causing cell arrest at M phase. We asked how the induced
changes in RUNX1 and A-E levels affect SAC signaling.
Accordingly, we characterized the cell cycle of NOC-treated
Kasumi-1Cont, Kasumi-1RX1-KD, Kasumi-1A-E-KD, and double-KD
Kasumi-1RX1/A-E-KD cells compared with cells treated with
vehicle (Figures 6A and 6B).
Overall, the ability of NOC-treated cells to arrest cell cycle at
M phase was inversely correlated with the proportion of dead/
apoptotic cells that accumulated in subG1 (Figure 6B). Specif-
ically, NOC-treated Kasumi-1RX1-KD and Kasumi-1A-E-KD cells
displayed a diminished or elevated capacity, respectively, to
arrest at M phase compared with NOC-treated Kasumi-1Cont
cells. Consequently, the proportion of their subG1 populations
was increased (Kasumi-1RX1-KD) or decreased (Kasumi-1A-E-KD)
(Figure 6B). Of particular relevance to this finding is the observa-
tion that cells expressing a C-terminal truncated isoform of A-E,
designated A-Etr, display enhanced mitotic progression upon
NOC treatment (Boyapati et al., 2007).
The complementary outcomes of these experiments suggest
that whereas RUNX1 positively regulates SAC activity, A-E
represses it. The findings that KD of A-E in Kasumi-1RX1-KD cells
(Kasumi-1RX1/AE-KD) restored SAC activity (Figure 6B) and
rescued cells from apoptosis (Figures 2B and 2C) support this1138 Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The Auconclusion. Significantly, the opposing regulatory effects of
A-E and RUNX1 on cellular gene expression noted above are
reflected here in their impact on the cell ability to arrest at
M phase and avoid cell death (Figure 6C). Thus, a threshold of
WT RUNX1 activity is essential in t(8;21) AML cells to counter
A-E-mediated inhibition of SAC signaling and thereby prevent
complete disruption of SAC and subsequent apoptosis, possibly
due to mitotic catastrophe.
Reduced RUNX1 Activity Affects inv(16) ME-1 and
Preleukemic CD34+/A-E Cell Viability
We next addressed whether the addiction of t(8;21) Kasumi-1
cell line to RUNX1 constitutes a common phenomenon in
leukemia associated with partial loss of RUNX1 function. Using
the inv(16) AML cell line ME-1 (Yanagisawa et al., 1991),
we examined the impact of RUNX1 KD on cell survival.
Significantly, RUNX1 KD (Figure 7A) produced a marked
increase in Annexin-V staining of both viable and nonviable
cells (Figure 7B), indicating RUNX1 KD-mediated enhancement
of apoptosis.
Cell-cycle analysis of untreated ME-1 cells identified a mixed
population of diploid and tetraploid cells (Figure S5), which is
characteristic of cells with attenuated mitotic functions. This
abnormal ME-1 cell-cycle profile made it unfeasible to record
cell death based on DNA content analysis. The data suggest
that the viability of inv(16) ME-1 cells, similarly to that of t(8;21)
Kasumi-1 cells, physiologically depends on RUNX1 activity.
The observations that inv(16) AML patients have no inactivating
mutations in RUNX1 (Do¨hner and Do¨hner, 2008; Goyama andthors
Figure 7. Requirement of Native RUNX1 for inv(16) ME-1 and Preleukemic CD34+/A-E Cell Viability
(A and B) RUNX1 activity is essential for survival of the inv(16) ME-1 cell line.
(A) qRT-PCR demonstrating RUNX1 KD in ME-1 cells. RNA from cells 24 hr posttransfection with RUNX1-targeting or NT siRNA was analyzed by qRT-PCR.
Results are the mean expression ± SE values of two experiments with similar results.
(B) KD of RUNX1 enhances apoptosis of ME-1 cell line. Cells were subjected to two successive rounds of electroporation (days 0 and 5) with either RUNX1-
targeting or NT siRNA. On day 10, apoptosis was monitored by FACS analysis of Annexin-V-stained cells. Results from one of four experiments with similar
findings are shown. See also Figure S5.
(C) qRT-PCR demonstrating RUNX1 KD in CD34+/A-E cells. RNA from CD34+/A-E cells 24 hr posttransfection with RUNX1-targeting or NT siRNA was analyzed
by qRT-PCR. Results are the mean expression ± SE values of two experiments with similar results.
(D) KD of RUNX1 increased apoptosis of CD34+/A-E cells. Twelve days after transduction with A-E lentiviral vector, cells were transfected with either RUNX1-
targeting or NT siRNA, and 4 days later GFP+ cells were assayed for Annexin-V staining by FACS. Histograms demonstrate a 2-fold increase in the proportion
of Annexin-V-positive CD34+/A-E cells among RUNX1 KD in comparison to control cultures. Results from one of three experiments with similar findings
are shown.Mulloy, 2011; Schnittger et al., 2011; Tang et al., 2009) or CBFb
(Heilman et al., 2006) further support this conclusion.
To evaluate the involvement of WT RUNX1 in the development
of A-E-mediated preleukemic cell phenotype, we used a preleu-
kemic cell model (Mulloy et al., 2002; Wunderlich and Mulloy,
2009) of human CD34+ progenitor cells transduced by A-E
expressing lentivirus (Millington et al., 2009). Transfection of
CD34+/A-E cells with siRNA against RUNX1 (Figure S6) resulted
in reduced expression of RUNX1 associated with an increased
proportion of Annexin-V+ positive cells as compared with cells
transfected with control NT siRNA (Figure 7C and 7D). This
finding indicates that RUNX1 activity is required for the preleuke-
mic CD34+/A-E cells viability and underscores the critical impor-
tance of the RUNX1/A-E balance for the leukemogenic process.
DISCUSSION
The evolvement of cancer cells involves the acquisition of
several hallmark capabilities (Hanahan and Weinberg, 2000,
2011), including accelerated proliferation, self-renewal, and
evasion of apoptosis. The prevailing notion is that t(8;21) AMLCell Reis initiated by a chromosomal translocation that occurs in BM
hematopoietic stem cells (HSCs). The resulting pre-LSCs that
express the oncogenic fusion protein self-renew and persist in
the BM (Goyama and Mulloy, 2011; Hatlen et al., 2012; Lam
and Zhang, 2012). During AML development, these pre-LSCs
undergo clonal transformation in a multistep process involving
additional genetic alterations that abrogate cell-growth regula-
tions (Thol and Ganser, 2010). The role of the chimeric A-E pro-
tein in the etiology of t(8;21) AML has beenwidely studied (Hatlen
et al., 2012; Lam and Zhang, 2012). However, the importance of
the native RUNX1 for the development of t(8;21) or inv(16) AML
subtypes remained obscure (Goyama and Mulloy, 2011).
We have shown that expression of native RUNX1 is crucial for
the survival of t(8;21) Kasumi-1 and inv(16) ME-1 AML cell lines,
as evidenced by the fact that RUNX1 KD evoked apoptotic cell
death. The medical significance of this leukemic cell addiction
to native RUNX1 is underscored by clinical data (reviewed in
Goyama andMulloy, 2011) showing that active RUNX1 is usually
maintained in patients with t(8;21) and inv(16) AML, whereas the
gene is frequently inactivated in other forms of AML (Do¨hner and
Do¨hner, 2008; Heilman et al., 2006; Preudhomme et al., 2009;ports 4, 1131–1143, September 26, 2013 ª2013 The Authors 1139
Schnittger et al., 2011; Tang et al., 2009). Furthermore, WT
RUNX1 is not only preserved but is frequently amplified in
patients with t(12;21) B cell acute lymphoblastic leukemia (ALL)
(Ma et al., 2001; Martı´nez-Ramı´rez et al., 2001; Peter et al.,
2009), suggesting that WT RUNX1 is also instrumental in
t(12;21) ALL development. However, a different mechanism
underlies the requirement of RUNX1 expression for cell growth
of the t(4;11) mixed lineage leukemia (MLL) MV4-11 and SEM
cell lines (Wilkinson et al., 2013).
Using Z-VAD-FMK and ImageStream System analysis, we
demonstrated that RUNX1 KD-induced Kasumi-1 cell death is
caspase dependent and associated with mitochondrial mem-
brane depolarization. Significantly, this cell death involves A-E
gain-of-function activity, as shown by the complete rescue
from apoptosis upon A-E KD in Kasumi-1RX1-KD cells. Consistent
with the involvement of A-E in Kasumi-1RX1-KD cell death, ChIP-
seq and gene expression data demonstrated opposing effects of
RUNX1 and A-E on their common target genes. Moreover, we
showed that RUNX1 can indirectly modulate the expression of
A-E uniquely regulated genes, suggesting that RUNX1 and A-E
compete for common cooperating TFs. Upon RUNX1 KD, these
TFs might be recruited by A-E, leading to the aberrant expres-
sion of RUNX1 uniquely regulated genes. This regulatory mech-
anism drives the overall alterations in gene expression that
characterize Kasumi-1RX1-KD cells. Compatible with this inter-
pretation, unique and shared A-E- and RUNX1-occupied regions
are enriched for the motif of ETS TF family members that interact
with the common DNA-binding domain of RUNX1 and A-E (Gu
et al., 2000; Gunther and Graves, 1994; Kim et al., 1999).
The notion that A-E is involved in Kasumi-1RX1-KD cell death
corresponds with the findings that A-E has inherent proapoptotic
activity (Burel et al., 2001; Lu et al., 2006) that opposes its leuke-
mogenicity. Our data suggest that WT RUNX1 counters this
proapoptotic activity and thereby contributes to the long-term
survival of t(8;21) preleukemic HSCs and consequently to the
development of leukemia. Indeed, RUNX1 is highly expressed
in CD34+ long-term HSCs, where it transcriptionally regulates
CD34 expression (Levantini et al., 2011). Moreover, A-E-trans-
duced CD34+ hematopoietic cells yield highly proliferative cyto-
kine-dependent cultures (Mulloy et al., 2002, 2003), suggesting
that the proapoptotic activity of A-E in CD34+ HSCs is attenu-
ated. Similarly, ectopic expression of C-S in cultured CD34+
hematopoietic cells produced long-term cell lines (Wunderlich
et al., 2006). This finding is compatible with our observation
that RUNX1 is also required for survival of the inv(16) leukemic
cell line ME-1. It also supports the conclusion that the develop-
ment of A-E- or C-S-mediated leukemia (CBF leukemias) (Speck
and Gilliland, 2002) depends on a delicate balance between the
oncogenic impact of the chimeric A-E and C-S proteins and the
antiapoptotic activity of RUNX1. Accordingly, the two deletion
mutants, A-E9a and CBFb-SMMHCd179-221, which accelerate
leukemia development in mice, have a lower capacity to inhibit
RUNX1 activity (Kamikubo et al., 2010; Kuo et al., 2006; Peterson
et al., 2007; Yan et al., 2004, 2006, 2009), attesting to the
crucial role of WT RUNX1 in the etiology of CBF leukemia.
Collectively, these data indicate that RUNX1 effectively inhibits
the chimeric protein-mediated apoptosis in leukemic cell lines,
but at which step?1140 Cell Reports 4, 1131–1143, September 26, 2013 ª2013 The AuA large number of studies have reported that RUNX1 plays an
important role in cell-cycle control by promoting G1 to S pro-
gression (reviewed in Friedman, 2009). We found that RUNX1
KD in the Kasumi-1 cell line caused enhanced A-E activity, re-
sulting in decreased expression of key mitosis-regulatory genes.
The aberrant expression of these RUNX1-regulated genes com-
promises mitotic functions, including SAC activity, leading to
apoptosis. This finding uncovers a role of RUNX1 as a regulator
of SAC functions and explains its importance for the viability of
Kasumi-1 (and likely ME-1) leukemic cell lines. Of note, RUNX1
activity increases during G2/M due to Cdk-mediated phosphor-
ylation of the protein (Friedman, 2009; Wang et al., 2007). During
M phase, the SAC maintains genomic stability by delaying cell
division until accurate chromosome segregation is achieved
(Lara-Gonzalez et al., 2012). Defects in SAC function generate
aneuploidy that could facilitate tumorigenesis (Holland and
Cleveland, 2012; Kops et al., 2005). Therefore, it is possible
that the initial reduction of RUNX1 activity in BM HSCs by
t(8;21) translocation contributes to the accumulation of addi-
tional genetic alterations that are required for onset of leukemia
(see Graphical Abstract). The finding that native RUNX1 is
required for the viability of preleukemic CD34+/A-E cells further
supports this notion.
EXPERIMENTAL PROCEDURES
Cell Culture and Expression Analysis
Kasumi-1 cells were purchased from the ATCC and maintained in RPMI-1640
supplemented with 20% fetal bovine serum (FBS), 2 mM L-glutamine, and 1%
penicillin-streptomycin at 37C and 5% CO2. ME-1 cells (Yanagisawa et al.,
1991) were obtained from DSMZ and grown in RPMI-1640 medium with
20% heat-inactivated FBS. Further information regarding the western blot,
qRT-PCR, and fluorescence-activated cell sorting (FACS) analyses is included
in the Extended Experimental Procedures.
ChIP-Seq
Two biological replicate ChIP-seq experiments were done for the specific
detection of either RUNX1- or AML1-ETO-bound genomic regions according
to standard procedures previously summarized in (Pencovich et al., 2011),
including several modifications as detailed in the Extended Experimental
Procedures.
siRNA Transfection
RUNX1-targeting, A-E-targeting, or NT control siRNA oligos (Thermo Scientific
Dharmacon) were electroporated into Kasumi-1, ME-1, and CD34+ cells as
detailed in the Extended Experimental Procedures.
Transcriptome Data Acquisition and Analysis
For transcriptome data acquisition, fluorescein isothiocyanate (FITC)-labeled
NT siRNA oligos (#2013, Block-it fluorescent oligo; Life Technologies) were
cotransfected with RUNX1-targeting, A-E-targeting, or control NT siRNAs,
and FITC+ cells were FACS isolated following 96 hr incubation. RNA was
obtained using miRNeasy (QIAGEN), its integrity was assessed using
Bioanalyzer (Agilent Technologies), and transcriptome analysis was con-
ducted as previously described (Pencovich et al., 2011), including several
modifications as detailed in the Extended Experimental Procedures.
Multispectral Imaging Flow Cytometry: ImageStream System
Analysis
For multispectral imaging flow cytometry, approximately 104 siRNA-treated
cells were collected per sample and data were analyzed using image analysis
software (IDEAS 4.0; Amnis) as detailed in the Extended Experimental
Procedures.thors
Generation of A-E-Expressing Human Hematopoietic Progenitor
CD34+ Cells
Human hematopoietic progenitor CD34+ cells were purchased from Invitrogen
(Life Technologies) and cultured according to the manufacturer’s instructions.
These StemPro CD34+ cells are human cord blood hematopoietic progenitor
cells derived from mixed donors. Human A-E cDNA was excised from
Addgene (http://www.addgene.org) pUHD-A-E plasmid using Age I and subcl-
oned into a modified Addgene pCSC lentiviral vector (Regev et al., 2010)
downstream from the cytomegalovirus promoter and upstream from the inter-
nal ribosomal entry site (IRES)-GFP cassette. Recombinant pseudo-lentiviral
particles were generated by cotransfection of the pCSC-A-E-IRES-GFP vector
and packaging DNA plasmids into human embryonic kidney (HEK) 293T cells.
Following isolation and purification of pCSC-A-E-IRES-GFP lentiviral particles,
they were introduced into CD34+ cells as previously described (Millington
et al., 2009). Following lentiviral transduction, the cells were harvested and
expression of A-E in HEK 293T and in GFP-expressing CD34+ cells was vali-
dated by western blotting and qRT-PCR, respectively.
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